ArticleInternational urology and nephrology2025
Safety and efficacy of WVTT (Rezum) in young men: preliminary data.
Article in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Sexual Function and Clinical Outcomes Following Rezūm Therapy for Benign Prostatic Hyperplasia: An Updated Systematic Review Including Large Prostate Volumes.Lower urinary tract symptoms · 2026Pooled it
- The impact of minimally invasive surgical therapy for Benign prostatic hyperplasia on sexual function: a systematic review and meta-analysis.Prostate cancer and prostatic diseases · 2026Review
- To Rezūm or Not to Rezūm: A Narrative Review of Water Vapor Thermal Therapy for Benign Prostatic Hyperplasia.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesWater vapor thermal therapy (WVTT) is one of the latest developed minimally invasive surgical treatments (MIST) for benign prostatic hyperplasia-related symptoms (LUTS/BPH). We focused on the functional outcomes of patients < 50 years treated with Rezūm for BPH.
methodsWe prospectively recorded data on patients treated with Rezūm at 5 institutions from April 2020 to June 2021. Uroflowmetry, prostatic specific antigen (PSA), ultrasonography assessing prostate volume and post voiding residual volume (PVR), the International Prostate Symptom Score (IPSS), International Index of Erectile Function (IIEF-5), and the question yes/no assessing ejaculatory dysfunction were recorded at baseline, and 3, 6 and 12 months later.
resultsTen patients were enrolled. The median operative time was 9 (IQR 8.25-13) min. All patients were dismissed a few hours after surgery with an indwelling urinary catheter that was removed after a median of 7 days (IQR 7-7). Each patient experienced an improvement both in terms of IPSS domain and in terms of maximal flow (Qmax) and PVR with a significative difference from the baseline observed at 3 months, stable until the last follow-up. Everyone maintained or gained antegrade ejaculation. No major post-operative complications were recorded, as just one patients experienced acute urinary retention after catheter removal.
conclusionsWVTT treatment is a feasible and safe minimally invasive option for patients < 50 y old with LUTS/BPH and showed optimal early functional outcomes.
Indexed as
Identifiers
40123015What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.